Nanoparticle properties and alveolar epithelial barrier/transport functions
Nanoparticle properties and alveolar epithelial barrier/transport functions
批准号:
8249083
负责人:
EDWARD DAVID CRANDALL
金额:
$35.72万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-06-15 至 2014-03-31
关键词:
Adherent CultureAdverse effectsAffectAir PollutantsAir PollutionAlveolarApicalBiologicalBlood CirculationBlood VesselsBreathingCaliberCardiovascular systemCell physiologyCellsCharacteristicsChargeDataDiffusionDimensionsDistalEdemaEnvironmental Air PollutantsEpithelialEpithelial CellsExposure toGene DeliveryHealthHomeostasisHumanIn VitroInflammationInjuryInstitutionInvestigationLeadLipid BilayersLungModelingMorbidity - disease rateNanotechnologyOrganParticulatePathway interactionsPharmaceutical PreparationsPolystyrenesPopulationPropertyRattusRegulationReportingRoleRouteScienceShapesSilicon DioxideStructure of respiratory epitheliumSurfaceTechnologyTestingThrombosisTissuesToxic effectUltrafinealveolar epitheliumambient particleatherogenesisbasebioimagingcytotoxicitydesignimprovedin vitro Modelin vivoin vivo Modelinjuredinsightinterestlung injurymetal oxidemortalitynanomaterialsnanoparticlenanoscaleparticlepollutantpreventrapid growthreconstitutiontraffickingultrafine particleunilamellar vesicleuptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Inhalation of ultrafine (nano)particles has been associated with adverse cardiovascular, pulmonary and
hematologic effects, localization of particles in blood vessels and end organs, and increased morbidity and
mortality in susceptible populations. Since the particles are inhaled, their most likely route of entry into the
systemic circulation is across the alveolar epithelium of the lung. Although utilization of nanoparticles due to
expansion of the science and application of nanotechnology is expected to markedly increase, the
mechanisms by which nanoparticles injure and/or are transported into/across alveolar epithelium are not well
known. Based on our preliminary data on lung injury/uptake/trafficking of several classes of nanoparticles
(composed of polystyrene, silica and metal (oxides)) with defined physicochemical characteristics and recent
reports on health effects of inhaled ultrafine air pollutant particulates, we hypothesize that interactions between
nanoparticles and alveolar epithelial cells i) can disrupt normal alveolar epithelial cell homeostasis and induce
changes in cellular properties and alveolar epithelial barrier function, ii) provide the primary portal of entry for
nanoparticles into the systemic circulation via transepithelial translocation pathways, and iii) are highly
dependent on physicochemical properties of the nanoparticles. Utilizing defined polystyrene, silica and metal
(oxide) nanoparticles in in vitro models (including our well-established primary cultured monolayers of rat or
human alveolar epithelial cells) and rat lungs in vivo, we will test these hypotheses by investigating the
following four major aims: 1) nanoparticle effects on active and passive barrier properties of alveolar
epithelium; 2) internalization, fate and effects of nanoparticles in alveolar epithelial cells; 3) trafficking of
nanoparticles across alveolar epithelium in vitro; and 4) nanoparticle internalization and trafficking in rat lungs
in vivo, correlating injury to/uptake into/trafficking across distal respiratory epithelium in vivo vs in vitro. In
addition, we will utilize simplified models of artificial lipid bilayers reconstituted on permeable filters and giant
unilamellar vesicles to determine the role(s) of passive mechanisms (e.g., diffusion) and/or disruption of lipid
bilayers in nanoparticle entry into/exit from alveolar epithelial cells. Findings from the investigations proposed
herein will provide insights into cytotoxicity and mechanisms of internalization/trafficking of nanoparticles with
defined physicochemical properties into/across the lung alveolar epithelium. Our major objective is to obtain
new information on nanoparticle interactions with alveolar epithelium in order to help understand effects on the
lung of inhaled manufactured nanoparticles and environmental air pollutant ultrafine particulates, point
directions for management of resultant deleterious effects, and lead to improved design of defined
nanoparticles for safer and more efficient biomedical applications (e.g., pulmonary drug/gene delivery).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MAPGen Knowledge Base (MAPGenKB) and Coordination Center
-
批准号:8870404
-
项目类别:
-
资助金额:$44.18万
-
财政年份:2011
-
负责人:EDWARD DAVID CRANDALL
-
依托单位:
MAPGen Knowledge Base (MAPGenKB) and Coordination Center
-
批准号:8324915
-
项目类别:
-
资助金额:$102.9万
-
财政年份:2011
-
负责人:EDWARD DAVID CRANDALL
-
依托单位:
MAPGen Knowledge Base (MAPGenKB) and Coordination Center
-
批准号:8499408
-
项目类别:
-
资助金额:$113.85万
-
财政年份:2011
-
负责人:EDWARD DAVID CRANDALL
-
依托单位:
MAPGen Knowledge Base (MAPGenKB) and Coordination Center
-
批准号:8138094
-
项目类别:
-
资助金额:$105.17万
-
财政年份:2011
-
负责人:EDWARD DAVID CRANDALL
-
依托单位:
MAPGen Knowledge Base (MAPGenKB) and Coordination Center
-
批准号:8692483
-
项目类别:
-
资助金额:$114.66万
-
财政年份:2011
-
负责人:EDWARD DAVID CRANDALL
-
依托单位:
Nanoparticle properties and alveolar epithelial barrier/transport functions
-
批准号:7735746
-
项目类别:
-
资助金额:$36.68万
-
财政年份:2009
-
负责人:EDWARD DAVID CRANDALL
-
依托单位:
Nanoparticle properties and alveolar epithelial barrier/transport functions
-
批准号:8450183
-
项目类别:
-
资助金额:$35.01万
-
财政年份:2009
-
负责人:EDWARD DAVID CRANDALL
-
依托单位:
Interactions of engineered nanomaterials with lung alveolar epithelium
-
批准号:7938765
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2009
-
负责人:EDWARD DAVID CRANDALL
-
依托单位:
Nanoparticle properties and alveolar epithelial barrier/transport functions
-
批准号:8063506
-
项目类别:
-
资助金额:$35.72万
-
财政年份:2009
-
负责人:EDWARD DAVID CRANDALL
-
依托单位:
Interactions of engineered nanomaterials with lung alveolar epithelium
-
批准号:7852903
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2009
-
负责人:EDWARD DAVID CRANDALL
-
依托单位:
ABSORPTION MECHANISMS FOR PEPTIDE/PROTEIN DRUGS VIA LUNG
-
批准号:6390641
-
项目类别:
-
资助金额:$64.4万
-
财政年份:1999
-
负责人:EDWARD DAVID CRANDALL
-
依托单位:
ABSORPTION MECHANISMS FOR PEPTIDE/PROTEIN DRUGS VIA LUNG
-
批准号:6053386
-
项目类别:
-
资助金额:$61.68万
-
财政年份:1999
-
负责人:EDWARD DAVID CRANDALL
-
依托单位:
Absorption mechanisms for peptide/protein drugs via lung
-
批准号:6796435
-
项目类别:
-
资助金额:$71.67万
-
财政年份:1999
-
负责人:EDWARD DAVID CRANDALL
-
依托单位:
ABSORPTION MECHANISMS FOR PEPTIDE/PROTEIN DRUGS VIA LUNG
-
批准号:6184822
-
项目类别:
-
资助金额:$63.15万
-
财政年份:1999
-
负责人:EDWARD DAVID CRANDALL
-
依托单位:
ABSORPTION MECHANISMS FOR PEPTIDE/PROTEIN DRUGS VIA LUNG
-
批准号:6527616
-
项目类别:
-
资助金额:$66.01万
-
财政年份:1999
-
负责人:EDWARD DAVID CRANDALL
-
依托单位:
ABSORPTION MECHANISMS FOR PEPTIDE/PROTEIN DRUGS VIA LUNG
-
批准号:6603910
-
项目类别:
-
资助金额:$67.68万
-
财政年份:1999
-
负责人:EDWARD DAVID CRANDALL
-
依托单位:
Absorption mechanisms for peptide/protein drugs via lung
-
批准号:7458881
-
项目类别:
-
资助金额:$74.4万
-
财政年份:1999
-
负责人:EDWARD DAVID CRANDALL
-
依托单位:
Absorption mechanisms for peptide/protein drugs via lung
-
批准号:6927132
-
项目类别:
-
资助金额:$73.96万
-
财政年份:1999
-
负责人:EDWARD DAVID CRANDALL
-
依托单位:
Absorption mechanisms for peptide/protein drugs via lung
-
批准号:7101061
-
项目类别:
-
资助金额:$74.29万
-
财政年份:1999
-
负责人:EDWARD DAVID CRANDALL
-
依托单位:
Absorption mechanisms for peptide/protein drugs via lung
-
批准号:7262437
-
项目类别:
-
资助金额:$74.0万
-
财政年份:1999
-
负责人:EDWARD DAVID CRANDALL
-
依托单位:
海外基金